HCPCS code P9070: Pooled pathogen reduced plasma billing guide

Key takeaways

HCPCS code P9070 describes plasma, pooled multiple donor, pathogen reduced, frozen, each unit, effective January 1, 2016.

P9070 is not a platelet rich plasma code, and a pooled multiple donor product is the opposite of an autologous one.

Medicare pays P9070 under the hospital outpatient system with status indicator R and APC 9534, at $55.78 per unit for CY 2026.

The Part B blood deductible applies to whole blood and packed red cells only, so it never touches a plasma line.

Pabau’s claims management software helps billing teams keep P-code lines, units, and transfusion records consistent before a claim goes out.

HCPCS code P9070 bills one unit of plasma, pooled multiple donor, pathogen reduced, frozen. It is a transfusion medicine product code. The plasma is collected from several donors, combined into a pool, run through a pathogen reduction process, and frozen for storage.

That descriptor matters because P9070 is widely miscited as a platelet rich plasma code. It is not one, and the confusion is easy to disprove. A pooled multiple donor product comes from other people’s blood, which makes it the definitional opposite of an autologous preparation.

This guide covers the official descriptor and what Medicare pays for the code. It sets out how the claim line is built and which diagnosis codes support it. A comparison table lines up the P-series codes closest to P9070, so the right one lands on the claim.

P9070 code details and official descriptor

P9070 sits in the P-series of HCPCS Level II. The Centers for Medicare and Medicaid Services (CMS) reserves that range for blood and blood products. CMS created the code effective January 1, 2016, and no revision since has changed what it describes.

Two things define the product and separate it from its neighbors in the P-series. The first is donor structure, meaning pooled from multiple donors rather than drawn from one. The second is the processing method, which here is pathogen reduction rather than solvent and detergent treatment.

Both facts live on the component label and in the blood bank issue record. Coders should read the label rather than infer the code from the clinical order. An order for “frozen plasma” does not say which product the transfusion service released.

Why P9070 is not a platelet rich plasma code

P9070 does not describe platelet rich plasma (PRP), and no revision of the code has ever carried a PRP descriptor. The mistake circulates widely enough that it is worth stating plainly, because it sends regenerative medicine claims to a transfusion product code.

Two clues settle it. Platelet rich plasma is a platelet concentrate, while P9070 describes plasma. PRP as practices use it is autologous, while P9070 is explicitly pooled from multiple donors.

Platelet rich plasma is coded elsewhere in the code set. The table below shows where those claims belong.

Anyone billing for a PRP injection in an orthopedic, wound care, or aesthetic setting should be looking at that table, not at P9070. Verify current coverage for those codes with the payer before the appointment, since PRP coverage remains narrow.

Clinical uses of pooled pathogen reduced plasma

Pooled pathogen reduced plasma is transfused for the same reasons as any other frozen plasma product. It replaces multiple coagulation factors at once, which is what separates plasma from a targeted factor concentrate.

Typical indications in the transfusion record include:

• Bleeding with multiple factor deficiencies: Liver disease, disseminated intravascular coagulation, and dilutional coagulopathy after large volume resuscitation
• Massive transfusion protocols: Plasma given in a fixed ratio alongside red cells and platelets during major hemorrhage
• Urgent anticoagulant reversal: Warfarin reversal in a bleeding patient when prothrombin complex concentrate is unavailable or contraindicated
• Therapeutic plasma exchange: Plasma used as the replacement fluid, most often for thrombotic thrombocytopenic purpura (TTP)
• Rare factor deficiencies: Congenital deficiencies for which no specific factor concentrate exists

Plasma is not indicated for volume expansion or for nutritional support. A claim that pairs P9070 with a diagnosis suggesting either use invites a medical necessity review, even where the product itself was correctly identified.

Medicare payment for P9070 in CY 2026

Medicare pays P9070 separately under the hospital Outpatient Prospective Payment System. The code carries status indicator R, the indicator reserved for blood and blood products. It sits in ambulatory payment classification (APC) 9534. For CY 2026 the national unadjusted payment rate is $55.78 per unit.

CMS sets blood product rates using a blood-specific cost-to-charge ratio that has been in place since 2005. That method converts hospital charges into estimated costs using ratios from recent cost reports. CY 2026 rates were built from CY 2024 claims and cost report data.

The two-year lag is worth remembering when a rate moves. A swing in the published amount reflects hospital charging behavior two years earlier, not a change in coverage or in the product itself.

Rates above are national unadjusted OPPS amounts for CY 2026, effective January 1, 2026. Your paid amount is adjusted by wage index and by any applicable outlier or copayment rules. Confirm the current figure in CMS Addendum B for the calendar year you are billing.

When P9070 is packaged instead of paid separately

Status indicator R does not guarantee a separate payment on every claim. When a blood product appears on the same claim as a comprehensive APC service, its cost is folded into the single C-APC payment. The P9070 line still belongs on the claim, but no separate amount is paid for it.

This is a common source of confusion in remittance review. A zero-paid P9070 line next to a C-APC procedure is usually correct packaging, not a denial, so it does not need an appeal.

The blood deductible does not apply to plasma

Medicare’s blood deductible covers the first three units of whole blood or packed red cells a beneficiary receives in a calendar year. It does not extend to other components. Plasma, platelets, fibrinogen, gamma globulin, and serum albumin all sit outside it, as does the cost of processing, storing, and administering blood.

A P9070 line should therefore never carry a blood deductible amount. If one appears on the remittance, treat it as a claim setup error worth checking rather than a patient balance to bill.

How to bill P9070: Units, revenue codes, and modifiers

P9070 is reported on the institutional claim by the facility whose transfusion service issued the product. Report one unit of P9070 for each unit of plasma issued and transfused, matching the blood bank record exactly.

The product line and the administration line are separate. Good medical billing workflows keep them aligned. A product billed without its administration line is one of the easier errors for a reviewer to spot.

The modifier rows above are there because both pairs get attached to P-codes by habit. JA and JB describe how a drug was given, and P9070 is not a drug. JW and JZ describe wastage from a single-dose vial, which a plasma unit is not.

Check your Medicare Administrative Contractor (MAC) billing guide for blood products before adding any modifier to a P-code line. Requirements are local, and an unnecessary modifier can turn a payable line into a rejected one.

ICD-10 diagnosis codes that support a P9070 claim

Medical necessity for a plasma transfusion rests on the diagnosis that explains the bleeding or the coagulopathy. The codes below reflect common indications for frozen plasma. Confirm each one against the payer’s own policy before you submit.

One recent change catches transfusion services out. ICD-10-CM expanded M31.1 into M31.10, M31.11, and M31.19, which left the old M31.1 as a non-billable parent code.

Plasma exchange claims still carrying M31.1 from an older charge template will reject for specificity. The fix is a template update rather than an appeal, so it is worth checking the stored code before the next rejection cycle.

P9070 compared with related plasma and platelet codes

Most P-series miscoding comes from one of two variables. Either the donor structure is wrong, or the processing method is. The table below lines up the codes closest to P9070 with their official descriptors.

Two rows in that table are worth flagging, because incorrect descriptors for both circulate online. P9035 carries no irradiation in its descriptor, and P9073 carries no CMV-negative or irradiated qualifier. The CMV-negative and irradiated platelet product is P9053.

The closest call in practice is P9070 against P9023. Both are pooled multiple donor frozen plasma, and only the processing method separates them. Read the component label to see which method the supplier used. The grid below plots the two label facts against each other.

Documentation requirements for P9070 claims

A plasma product line is supported by the transfusion record, not by the clinical note alone. Payers reviewing a P9070 claim want to see that the unit was ordered, issued, and given, and that the product matches the code.

• Transfusion order: The ordering provider’s request for plasma, with the clinical indication recorded
• Blood bank issue record: The unit number, component type, and the number of units released to the patient
• Component label detail: Evidence that the product was pooled multiple donor and pathogen reduced, which distinguishes P9070 from P9023
• Transfusion administration record: Start and stop times, volume transfused, and the vital signs taken during the transfusion
• Supporting ICD-10-CM codes: At least one diagnosis explaining the coagulopathy or the bleeding episode
• Laboratory results: The coagulation studies or clinical findings that prompted the transfusion
• Any transfusion reaction workup: Documented if a reaction occurred, including the products involved

Blood bank records are already subject to their own retention rules under transfusion service standards. Keep the billing documentation aligned with those records so that a payer audit and an accreditation review reach the same conclusion.

Common P9070 billing errors

Most P9070 problems are identification problems rather than coverage problems. The product is usually covered, so the denial tends to come from a mismatch between the code, the unit count, and the record.

Knowing which of these applies saves the work of drafting an appeal that was never going to land:

• Using P9070 for platelet rich plasma: The single most common error, and it puts a regenerative medicine service on a transfusion product code
• Confusing P9070 with P9023: Both are pooled frozen plasma, and the processing method on the label decides which code is right
• Confusing P9070 with P9071: The single donor pathogen reduced code, which pays at a very different rate
• Unit count mismatches: Billed units that do not match the number of units the blood bank issued
• Missing administration lines: The product billed without the revenue code 0391 line and its transfusion procedure code
• Appealing correct packaging: Treating a zero-paid line on a comprehensive APC claim as a denial
• Stale diagnosis templates: Submitting a parent code such as M31.1 after ICD-10-CM expanded it into more specific codes

Reading the denial codes on the remittance against that list turns it into a short diagnosis. A specificity rejection points at the diagnosis template. A quantity denial points at the issue record.

How Pabau keeps blood product claim lines accurate

P-series billing fails quietly. A charge master row keeps producing a familiar code while the product on the shelf has changed. Nobody notices until a batch of remittances comes back short.

Practice management software like Pabau keeps the clinical record and the billing record on one system. The codes attached to an encounter stay tied to what was documented. Charges, invoices, and payments sit against the same patient record instead of in separate spreadsheets.

Pabau’s claims management software tracks what was submitted, what was paid, and what came back rejected. Billing teams can see denial patterns by code rather than reconstructing them from individual remittances at month end.

Every Pabau subscription includes the full feature set, so reporting and claims tools are available from day one rather than unlocked at a higher tier. Onboarding is structured, with your existing records and codes migrated before you go live.

Keep every code line traceable to its record

Pabau keeps clinical documentation, charges, and claim outcomes on one system. Billing teams can trace any HCPCS line back to the record that supports it. You spend less time reconstructing evidence for a payer review.

Book a demo

Conclusion

P9070 is a straightforward code once the product is identified correctly. It bills a unit of pooled multiple donor, pathogen reduced, frozen plasma. Medicare pays it separately under OPPS unless the claim carries a comprehensive APC service.

The risk sits upstream of the claim. Say your charge master maps P9070 to platelet rich plasma, or fails to distinguish it from P9023 and P9071. Every line it produces is then wrong before anyone reviews it. Check the mapping against the component label once, and the recurring denials stop.

The trade-off worth remembering is that plasma codes reward precision over volume. A single correct descriptor mapping saves more revenue than any appeal you write afterward. Book a demo to see how Pabau keeps coding, documentation, and claim outcomes on one record.

Continue your research

Need a framework for managing claim denials? Denial management in healthcare walks through tracking, appealing, and preventing the denials that repeat across HCPCS and CPT claims.

Want the revenue cycle context for HCPCS billing? What is revenue cycle management explains how a code line fits into the workflow from patient intake to payment posting.

Chasing first-pass acceptance on your claims? What is a clean claim covers the checks that get a claim paid on submission instead of sending it into an appeals cycle.

Frequently asked questions